News – Page 684 – Endpoints News

Israel's VBL Therapeutics hit with CMC delays in ovarian cancer study; Novo Holdings buys out diagnostics player BBI

4 years ago

Mississippi sues Eli Lilly, Sanofi and Novo over insulin prices as interchangeable biosimilars may arrive soon

4 years ago

Just shy of its 1-year anniversary, radiopharmaceuticals platform play RayzeBio bags another megaround

4 years ago

Exscientia spends SoftBank's cash in bid to edge out AI rivals

4 years ago

AstraZeneca's Covid-19 antibody cocktail misses the mark in preventing symptoms post-exposure

4 years ago

CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida

4 years ago

Sage's second chance at depression hits the PhIII primary, but questions remain over durability, side effects

4 years ago

SoftBank, Cormorant lead hefty $210M injection for Umoja's three-in-one cancer immunotherapy play

4 years ago

Going after the phenomenon of 'regRNA,' Rick Young's Camp4 secures a launch round to push two programs forward

4 years ago

Swiss-based upstart marches toward the clinic with a unique approach to fibrosis treatment

4 years ago

Ex-FDA commish Stephen Hahn joins Flagship, a venture group that spawned Covid-19 vaccine maker Moderna

4 years ago

FDA’s Cavazzoni calls for adcomms to ‘get back to the substance’

4 years ago

Biogen signals a big PhIII failure as the lead gene therapy in their $800M Nightstar buyout goes down in flames

4 years ago

Bayer flushes money into the Nordics with $303M down payment on new Finnish plant, expansion

4 years ago

Recall report: Another drugmaker is pulling its version of metformin off shelves after a carcinogen scare

4 years ago

FDA pushes back Ascendis' PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ...

4 years ago

Terns Pharmaceuticals touts safety data from an ex-Eli Lilly candidate in the hunt for NASH treatment

4 years ago

‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with ...

4 years ago

A snakebit biotech receives second CRL for reformulated pain med, potentially putting the kibosh on its chances

4 years ago

Looking beyond the pandemic, Moderna appoints J&J veteran Paul Burton as new CMO

4 years ago

Top analyst maps a rocky road for Vertex — unless they adopt a $10B M&A campaign to save the pipeline

4 years ago

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

4 years ago

Covid-19 roundup: Germany puts J&J on the hotseat for vaccine backorder; Top EMA official suggests forgoing ...

4 years ago

75M vaccine doses wasted: FDA spells out Emergent facility deficiencies at length in new memo

4 years ago

First page Previous page 681 682 683684685 686 687 Next page Last page